Vertex Pharmaceuticals Inc. Stock

Gene-editing technology has moved from science fiction to clinical reality, forcing investors to choose between commercial leaders and early-stage innovators. Deciding between CRISPR Therapeutics AG

The gene-editing niche of the biotech industry is gaining momentum, as various companies focused on these techniques -- which allow scientists to alter patients' DNA to treat some diseases -- have

If you had invested $20,000 in Vertex Pharmaceuticals (NASDAQ: VRTX) in its IPO in 1991 and held onto its shares, you'd have over $1 million today, considering the company's strong 14% compound

Intuitive Surgical (NASDAQ: ISRG) and Vertex Pharmaceuticals (NASDAQ: VRTX) have posted excellent returns over the past 10 years, but they are encountering obstacles right now. Both healthcare

CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech company, achieved a major milestone when it earned approval for the first CRISPR-based medicine in 2023. However, the company has significantly

Vertex Pharmaceuticals (NASDAQ: VRTX) and Mirum Pharmaceuticals (NASDAQ: MIRM) are two biotech stocks that share the same blueprint. They are focusing on rare diseases with highly unmet medical

Over the past 10 years, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered market-beating returns. The company owes this performance to its dominance in the cystic fibrosis (CF) drug market. Vertex

Investors looking for stocks that can turn a modest portfolio into a multimillion-dollar nest egg often find what they're looking for in the biotech industry. For several years, CRISPR Therapeutics

One of the best ways to earn great returns in equity markets is to buy high-quality stocks and hold them for a long time. But it's not always simple to know which corporations have what it takes to

Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly underperformed broader equities over the past 12 months, with its shares down 10% since March of 2025, compared to a 15% gain for the S&P 500.

Over the past five years, CRISPR Therapeutics' (NASDAQ: CRSP) shares have significantly lagged broader equities. That's despite the company earning approval for its first commercialized medicine,

Drug stocks can be somewhat volatile. Things like clinical setbacks or patent cliffs can sink their stock prices or erode their profits and market share. However, one good thing about companies in

Eli Lilly (NYSE: LLY) and Vertex Pharmaceuticals (NASDAQ: VRTX) have several things in common. Both are among the more prominent drugmakers in the world, and both have delivered market-beating

Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy few years. The biotech company, known for its leadership in the cystic fibrosis (CF) treatment market, has proven its ability to broaden into

Vertex Pharmaceuticals (NASDAQ: VRTX) has encountered several clinical setbacks over the past 18 months, including for two products in its growing pain medicine franchise. Even with recent approvals

On February 17, 2026, Tensile Capital Management LP reported selling 384,415 shares of Vertex (NASDAQ:VERX) in the fourth quarter, an estimated $8.32 million trade based on quarterly average

Everyone should save money for retirement, since programs such as Social Security aren't meant to replace workers' entire income and face potential cuts. Building a big nest egg for your post-work

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously considered untreatable. That's why biotechs that specialize in gene

Will the healthcare sector finally rebound in 2026, after underperforming broader equities in recent years? It's hard to know for sure. But rather than avoiding the entire industry because of recent

Over the past year, shares of Centessa Pharmaceuticals (NASDAQ: CNTA) have significantly outperformed broader equities as the biotech has made tremendous progress with a promising pipeline

Turning $100,000 into $1 million in a decade requires a compound annual growth rate (CAGR) of almost 26%. That's miles above the market's long-term average. It's also even better than a company like